Amarin--2019's Biggest Buyout Target for Big Pharma
Amarin (AMRN US), a US-listed biotech firm, presented the full results of its "Reduce-It" (RI) clinical trial at a conference for the American...
4.7k Views
Nippon Suisan (1332)--Stalled EPA Sales to Amarin
Nippon Suisan ("Nissui") has a new fish-oil EPA plant with 420 tons/year in capacity and is currently operating at 50% utilization. The company...
2.3k Views
Is It a Nikkei BOJ Squeeze on Nikkei 225 Low Float Names? Or Just FamilyMart Being FamilyMart?
A comment from a Smartkarma client prompted me to dig through this. It was an interesting comment suggesting the high weight Nikkei 225 names,...
574 Views
Japan: Autumn Results & Revision Scores - Peer Groups - 'Four Quadrant' Analysis
PEER GROUP SCORES INTRODUCTION - Following on from our earlier update on the Market Composite & Sectors, this insight will cover the Results...
484 Views
Nippon Suisan--Amarin Reports 25% Risk Reduction in Clinical Trial, Better than Lipitor Results
We wrote a report on Nippon Suisan ("Nissui"), a 110-year-old fish trader and food products company in Japan, on September 3rd (Nippon Suisan...
1.5k Views